Patel NA, Acaba-Berrocal LA, Hoyek S, Fan KC, Martinez-Castellanos MA, Baumal CR, et al. Practice patterns and outcomes of intravitreal anti-VEGF injection for retinopathy of prematurity. an international multicenter study. Ophthamology. 2022;129:1380–8.

Article  Google Scholar 

Raghuveer TS, Zackula R. Strategies to prevent severe retinopathy of prematurity: a 2020 update and meta-analysis. Neoreviews. 2020;21:e249–e263. https://doi.org/10.1542/neo.21-4-e249

Article  PubMed  Google Scholar 

Hartnett ME, Stahl A. Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity. Ophthalmol Ther. 2023;12:2241–52.

Article  PubMed  PubMed Central  Google Scholar 

Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.

Article  Google Scholar 

Simmons AB, Bretz CA, Wang H, Kunz E, Hajj K, Kennedy C, et al. Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy. Angiogenesis. 2018;21:751–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sauer L, Chandler M, Hartnett ME. Extending peripheral retinal vascularization in retinopathy of prematurity through regulation of VEGF signaling. Am J Ophthalmol. 2023;260:190–9. https://doi.org/10.1016/j.ajo.2023.12.008. PMID: 38141904.

Article  CAS  PubMed  Google Scholar 

Mintz-Hittner HA, Kennedy KA, Chuang ZA, for the BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl J Med. 2011;364:603–15. https://doi.org/10.1056/NEJMoa1007374

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, et al. Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654–6.

Article  PubMed  PubMed Central  Google Scholar 

Freedman SF, Hercinovic A, Wallace DK, Kraker RT, Li Z, Bhatt AR, et al. Low and very low dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes. Ophthalmology. 2022;129:1120–8. https://doi.org/10.1016/j.ophtha.2022.05.019

Article  PubMed  Google Scholar 

Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birth weight infants with retinopathy of prematurity (RAINBOW): an open label randomized controlled trial. Lancet. 2019;394:1551–59.

Article  CAS  PubMed  Google Scholar 

Stahl A, Sukgen EA, Wu W-C, Lepore D, Nakanishi H, Mazela J, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity. the FIREFLEYE randomized clinical trial. JAMA. 2022;328:348–59. https://doi.org/10.1001/jama.2022.10564

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moshfeghi DM. Effect of intravitreal aflibercept versus laser photocoagulation for retinopathy of prematurity: results from the phase 3 BUTTERFLEYE trial. Invest Ophthalmol Vis Sci. 2023;64:5126.

Google Scholar 

Stahl A, Azuma N, Wu W-C, Lepore D, Sukgen E, Nakanishi H, et al. Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study. Eye. 2024; https://doi.org/10.1038/s41433-024-02948-y

Chang E, Josan AS, Purohit R, Patel CK, Xue K. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for treatment of retinopathy of prematurity. Ophthalmology. 2022;129:1389–401. https://doi.org/10.1016/j.ophtha.2022.06.042

Article  PubMed  Google Scholar 

Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327–33. https://doi.org/10.1016/j.ajo.2011.07.005

Article  CAS  PubMed  Google Scholar 

Wu WC, Lein R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391–7. https://doi.org/10.1001/jamaophthalmol.2014.5373

Article  PubMed  Google Scholar 

Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254:31–36. https://doi.org/10.1007/s00417-015-2996-0

Article  CAS  PubMed  Google Scholar 

Huang CY, Lein R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256:479–87. https://doi.org/10.1007/s00417-017-3878-4

Article  CAS  PubMed  Google Scholar 

Khalili S, Shifrin Y, Pan J, Belik J, Mireskandari K. The effect of a single anti-vascular endothelial growth factor injection on neonatal growth and organ development: in-vivo study. Exp Eye Res. 2018;169:54–59. https://doi.org/10.1016/j.exer.2018.01.020

Article  CAS  PubMed  Google Scholar 

Kennedy KA, Mintz-Hittner HA, for the BEAT-ROP Co-operative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22:61–65. https://doi.org/10.1016/j.jaapos.2017.10.006

Article  PubMed  Google Scholar 

Marlow N, Stahl A, Lepore D, Fielder A, Reynolds JD, Zhu Q, et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021;5:698–707. https://doi.org/10.1016/S2352-4642(21)00195-4

Article  CAS  PubMed  Google Scholar 

Marlow N, Reynolds JD, Lepore D, Reynolds AR, Stahl A, Hao H, et al. Ranibizumab versus laser therapy for treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomized trial. eClinicalMedicine. 2024;71:102567 https://doi.org/10.1016/j.eclinm.2024.102567

Article  PubMed  PubMed Central  Google Scholar 

Fierson WM, American Academy of Pediatrics Section of Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142:e20183061 https://doi.org/10.1542/peds.2018-3061

Article  PubMed  Google Scholar